“Opioid shortages leave US hospitals scrambling” and like titles are making headlines. Manufacturing problems of injectable opioids has nearly ground to a halt. Hospital pharmacies are therefore faced with a shortage of needed staple medications. With manufacturing of injectable opioids not expected to be restored to its full capacity until the first quarter of 2019, hospital pharmacies are faced with the need to compound product for in house use. The FDA requires each compounded product to undergo sterility testing according to USP <797>. As MSI has been issued DEA clearance and is therefore able to accept Class I-V compounds, please contact one of our representatives at 713-663-6888 to address those testing requirements necessary to meet your needs.